Aole Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aole Zheng has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Qingfeng He
Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmaceutical Sciences Fudan University Shanghai China
3 shared publications - Xiaoqiang Xiang
Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China
3 shared publications - Dongsheng Yang
Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, SanFrancisco , San Francisco, California
2 shared publications - Wen Yao Mak
Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy Fudan University Shanghai China
2 shared publications Xiao Zhu
2 shared publications- Xiao Zhu
Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmaceutical Sciences, Fudan University, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by KEAI Publishing in Pharmacoeconomics and Policy
- Vol. 2 (2) , 110-118
Linked pharmacometrics-pharmacoeconomics model for cost-effectiveness analysis of tacrolimus in liver transplant patients from real-world data
- 1 June 2026
- Published by KEAI Publishing in Pharmacoeconomics and Policy
- Vol. 2 (2) , 110-118
Open AccessLinked pharmacometrics-pharmacoeconomics model for cost-effectiveness analysis of tacrolimus in liver transplant patients from real-world data
- 21 December 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (5) , 1317-1330
Population Time‐to‐Event Modeling of Pregnancy Loss Risk Following Frozen Embryo Transfer: A Real‐World Study in Chinese Women
Pregnancy loss after frozen embryo transfer (FET) remains an under‐recognized complication in assisted reproductive technology (ART), particularly in non‐Western settings. Existing prediction models rarely capture evolving hazards over gestation or externally validated. To address this, we developed and externally validated a parametric time‐to‐event model to predict the dynamic risks of pregnancy loss following FET using a large real‐world Chinese cohort. The model incorporated routinely available clinical variables, including maternal demographics, progesterone concentration, endometrium thickness, and endometrium preparation protocols. A Gompertz distribution model captured the time‐dependent hazard trajectory. Model performance was externally validated in two temporal cohorts, as well as in older women (≥40 years) and ethnic minority subgroups. Clinical utility was assessed by decision‐curve analysis (DCA). Among 21,242 conceptions, 17.6% resulted in miscarriage or stillbirth, with risks peaking in the first trimester. Maternal age showed a nonlinear effect: compared with reference age 32, hazard increased by 67% at age 40 and more than doubled by age 45. Higher weight accelerated risk over time. Protective factors included greater endometrial thickness, higher progesterone levels, and use of mild‐ (hazard ratio, HR 0.80, 95% CI: 0.753–0862), late‐ (HR 0.90, 95% CI: 0.798–0.951), or modified‐late stimulation (HR 0.80, 95% CI: 0.732–0.863) protocols. DCA indicated that model‐guided risk‐stratification strategies offered clear net benefit in older women across a broader range of risk threshold. This validated, time‐resolved model supports individualized risk‐stratification strategies and informed treatment decisions in FET‐based ART across diverse clinical settings in China.
- 21 December 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (5) , 1317-1330
Population Time‐to‐Event Modeling of Pregnancy Loss Risk Following Frozen Embryo Transfer: A Real‐World Study in Chinese Women
Pregnancy loss after frozen embryo transfer (FET) remains an under‐recognized complication in assisted reproductive technology (ART), particularly in non‐Western settings. Existing prediction models rarely capture evolving hazards over gestation or externally validated. To address this, we developed and externally validated a parametric time‐to‐event model to predict the dynamic risks of pregnancy loss following FET using a large real‐world Chinese cohort. The model incorporated routinely available clinical variables, including maternal demographics, progesterone concentration, endometrium thickness, and endometrium preparation protocols. A Gompertz distribution model captured the time‐dependent hazard trajectory. Model performance was externally validated in two temporal cohorts, as well as in older women (≥40 years) and ethnic minority subgroups. Clinical utility was assessed by decision‐curve analysis (DCA). Among 21,242 conceptions, 17.6% resulted in miscarriage or stillbirth, with risks peaking in the first trimester. Maternal age showed a nonlinear effect: compared with reference age 32, hazard increased by 67% at age 40 and more than doubled by age 45. Higher weight accelerated risk over time. Protective factors included greater endometrial thickness, higher progesterone levels, and use of mild‐ (hazard ratio, HR 0.80, 95% CI: 0.753–0862), late‐ (HR 0.90, 95% CI: 0.798–0.951), or modified‐late stimulation (HR 0.80, 95% CI: 0.732–0.863) protocols. DCA indicated that model‐guided risk‐stratification strategies offered clear net benefit in older women across a broader range of risk threshold. This validated, time‐resolved model supports individualized risk‐stratification strategies and informed treatment decisions in FET‐based ART across diverse clinical settings in China.
- Open Access
- 18 February 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (5) , 828-839
PBPK Modeling: Empowering Drug Development and Precision Dosing in China
Physiologically based pharmacokinetic (PBPK) modeling, a cornerstone of model‐informed drug development and model‐informed precision dosing, simulates drug disposition in the human body by integrating physiological, biochemical, and physicochemical parameters. While PBPK modeling has advanced globally since the 1970s, China's adoption of this technology has followed a distinctive path, characterized by accelerated growth over the past 2 decades. This review provides a comprehensive analysis of China's contributions to PBPK modeling, addressing knowledge gaps in publication trends, application domains, and platform preferences. A systematic literature search yielded 266 original PBPK research articles from PubMed up to August 08, 2024. The analysis revealed that drug disposition and drug–drug interaction studies constitute the largest proportion of PBPK analyses in China. Chinese universities and hospitals emerge as the leading contributors to PBPK research among institutions in China. Although established commercial PBPK platform such as GastroPlus and Simcyp remain popular within the Chinese pharmaceutical industry, open‐source platforms like PK‐Sim are gaining significant traction in PBPK applications across China. This review underscores the transformative potential of PBPK modeling in drug development within China, offering valuable insights into future directions and challenges in the field.
- 18 February 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (5) , 828-839
Open AccessPBPK Modeling: Empowering Drug Development and Precision Dosing in China
Physiologically based pharmacokinetic (PBPK) modeling, a cornerstone of model‐informed drug development and model‐informed precision dosing, simulates drug disposition in the human body by integrating physiological, biochemical, and physicochemical parameters. While PBPK modeling has advanced globally since the 1970s, China's adoption of this technology has followed a distinctive path, characterized by accelerated growth over the past 2 decades. This review provides a comprehensive analysis of China's contributions to PBPK modeling, addressing knowledge gaps in publication trends, application domains, and platform preferences. A systematic literature search yielded 266 original PBPK research articles from PubMed up to August 08, 2024. The analysis revealed that drug disposition and drug–drug interaction studies constitute the largest proportion of PBPK analyses in China. Chinese universities and hospitals emerge as the leading contributors to PBPK research among institutions in China. Although established commercial PBPK platform such as GastroPlus and Simcyp remain popular within the Chinese pharmaceutical industry, open‐source platforms like PK‐Sim are gaining significant traction in PBPK applications across China. This review underscores the transformative potential of PBPK modeling in drug development within China, offering valuable insights into future directions and challenges in the field.
- Open Access
- 30 March 2024
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 196, 106757
Modeling the complexity of drug-drug interactions: A physiologically-based pharmacokinetic study of Lenvatinib with Schisantherin A/Schisandrin A
- 30 March 2024
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 196, 106757
Open AccessModeling the complexity of drug-drug interactions: A physiologically-based pharmacokinetic study of Lenvatinib with Schisantherin A/Schisandrin A